Friday, 12 September, 2025г.
russian english deutsch french spanish portuguese czech greek georgian chinese japanese korean indonesian turkish thai uzbek

пример: покупка автомобиля в Запорожье

 

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 studyУ вашего броузера проблема в совместимости с HTML5
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute discusses if one regimen is preferred over another in the 1st line treatment of metastatic colorectal cancer, due to the phase 3 CALGB/SWOG 80405 study
Опубликовано: 15-06-2016
Похожие видео
Prof. Fortunato Ciardiello, MD, PhD, Seconda Università di Napoli

Prof. Fortunato Ciardiello, MD, PhD, Seconda Università di Napoli08:15

Prof. Dr. med. Volker Heinemann: Comments on FIRE-3 & CALGB/SWOG 80405

Prof. Dr. med. Volker Heinemann: Comments on FIRE-3 & CALGB/SWOG 8040507:00

Debate 1: First-line Treatment of Metastatic Colorectal Cancer - CALGB 80405

Debate 1: First-line Treatment of Metastatic Colorectal Cancer - CALGB 8040513:18

Dr. Muro on Results of PaFF-K Study in Colorectal Cancer

Dr. Muro on Results of PaFF-K Study in Colorectal Cancer01:20

Мой аккаунт

Вход / Log In